Horizon Pharma (HZNP) Tops Q4 EPS by 13c, Offers FY Guidance

Horizon Pharma (NASDAQ: HZNP) reported Q4 EPS of $0.67, $0.13 better than the analyst estimate of $0.54. Revenue for the quarter came in at $355.5 million versus the consensus estimate of $334.22 million.

GUIDANCE:

Horizon Pharma sees FY2019 revenue of $1.23-1.25 billion, versus the consensus of $1.24 billion.

• Full‐year 2019 adjusted EBITDA is expected to range between $440 million and $455 million

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Hasbro (HAS) brand strength sees earnings top expectations
• Ribbon Communications (RBBN) Misses Q1 EPS by 2c; offers guidance
• Teledyne Technologies (TDY) Misses Q1 EPS by 8c ; Offers Guidance